OR WAIT null SECS
The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more.
November 18, 2026
Video
Sparsentan, B cell therapies, and TRPC6 and APOL1 inhibitors may each fit a different stage and cause of FSGS.
A renal pathologist explains how biopsy findings, clinical context, anti-nephrin antibodies and genetics shape FSGS workup.
November 15, 2026
Podcast
Hiddo Heerspink, PharmD, PhD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack finerenone’s FIND-CKD data in FSGS.
July 08, 2026
Article
Catch up on some of the biggest FDA news, clinical trial updates, and featured HCPLive coverage from the first half of 2026.
June 05, 2026
The phase 3 TURING trial found rituximab slashed relapse rates in adults with minimal change disease and FSGS, offering a steroid-sparing alternative.
June 01, 2026
A clinician explains how sparsentan is changing treatment strategies for patients with FSGS.
Chung, MD, explains why sparsentan remains valuable in FSGS despite a negative eGFR endpoint.
May 04, 2026
Catch up on 5 nephrology headlines you missed in April 2026, including WCN coverage, FDA updates, and trial data.
April 19, 2026
Listen to our conversation with Trachtman about sparsentan's recent FDA approval for FSGS.
April 14, 2026
A DUPLEX study investigator explains the data behind sparsentan's approval by the FDA.